Repligen Seeks To Block Launch Of Bristol-Myers Drug

Law360 (January 6, 2006, 12:00 AM EST) -- A Massachusetts biotech company has rekindled its battle with Bristol-Myers Squibb over the patent for a new arthritis drug, which the global pharmaceutical company plans to launch next month.

The lawsuit, filed by Repligen Corp., marks a change in tactic for the biotech company, which previously sued Bristol-Myers over ownership rights to a different patent for the same technology.

Repligen lost those legal bids. But now the company is trying a new approach, suing Bristol-Myers for infringement of another patent, issued in 2004 to the same...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.